Category: Pharma Industry Trends
-
Xarelto Clinical Trial Issue May Lead To Dosage Level Testing For All New Oral Anticogaulant Drugs
Medical Journal Article Says FDA Might Make This Change For Patients Using Eliquis, Pradaxa, Savaysa, Or Xarelto (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: Xarelto trial results reaffirmed despite faulty device (Reuters,…
-
Is Eliquis Safer Than Xarelto And Pradaxa If It Causes Fewer Dangerous Major Bleeding Events
Perhaps, But Neither Eliquis Nor Xarelto Have Any Specific Reversal Agent To Stop An Acute Bleed Once It Starts; Only Pradaxa Does (Posted by Tom Lamb at DrugInjuryWatch.com) During the American Heart Association…
-
New Anti-Clotting Drug Savaysa Can Be Dangerous As It Has No Treatment Approved To Reverse The Anti-Coagulant Effect In Cases Of Bleeding
Like Eliquis, Xarelto, And Pradaxa, This New Blood-Thinner Is Being Sold By Drug Companies At A Time When Profits May Be Taking Priority Over Patient Safety (Posted by Tom Lamb at DrugInjuryWatch.com) …
-
Multaq: Increased Risks Of Side Effects, Including Death, Outweigh Any Benefits Say Researchers Who Reviewed Clinical Data
In Addition, They Are Highly Critical Of Relationship The Sanofi Aventis Drug Company Had With Those Doctors Who Developed Prescribing Guidelines (Posted by Tom Lamb at DrugInjuryWatch.com)As we know, now, since being approved by the FDA…
-
Is Plavix-Related Hemophilia Side Effect Significant Enough For Label Change In Europe But Not In U.S.
Sanofi Has Sent Out "Dear Doctor" Letters About The Association Of Plavix (Clopidogrel) Acquired Hemophilia There — Why Not Here, Too (Posted by Tom Lamb at DrugInjuryWatch.com) ______________________________________________________________________________ UPDATE: This label revision regarding hemophilia…
-
Two Conferences About Big Pharma Conduct: One Past (Selling Sickness 2013), One Future (PharmedOut’s 4th Annual Conference)
At Their Respective Websites, You Can See What You Have Missed And What You Can Look Forward To In Washington, DC (Posted by Tom Lamb at DrugInjuryWatch.com) In February I attended Selling Sickness 2013 –…
-
“Selling Sickness 2013” Conference In February Will Focus On Various Aspects Of Pharmaceutical Industry
Academic Medical Reformers, Consumer Activists, Health Journalists, And Others Will Gather In Washington, DC To Discuss Big Pharma Conduct and Practices (Posted by Tom Lamb at DrugInjuryWatch.com)I want to let you know about an…
-
Epogen / Procrit / Aranesp: The July 2012 News Report Which Tells Story Of Big Pharma Profits Over Patient Safety And Drug Efficacy
Once The FDA Started Paying Attention The Writing On The Wall Became Apparent, Albeit Too Late For Some (Posted by Tom Lamb at DrugInjuryWatch.com) This lengthy and well-presented news report, "Anemia drugs made billions, but…
-
Two New Books About Drug Injury Lawsuits, “All The Justice Money Can Buy” and “The Trial”
First Covers One Of The Early Vioxx Cases, Second Is Legal Thriller Fiction With Parallels To Ketek Fiasco (Posted by Tom Lamb at DrugInjuryWatch.com)As the summer reading season draws near, we take a break…
-
Medical Journal Withdraws Article About Januvia And Byetta After It Gets Letters From Two Drug Companies
April 2011 Edition Of BMJ Breaks News And Provides Insight From One Who Saw An Increased Risk Of Pancreatitis (Posted by Tom Lamb at DrugInjuryWatch.com) According to a news item published April 11, 2011 by…